Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.66 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.59 |
| ▸ | MIF | P14174 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26317745 | 1.00 | DDB1 (0.74) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL26323698 | 1.00 | DDB1 (0.74) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL26317743 | 1.00 | DDB1 (0.74) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL26317742 | 0.99 | DDB1 (0.76) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL26317740 | 0.97 | DDB1 (0.76) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL23772794 | 0.96 | DDB1 (0.69) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL20260257 | 0.96 | DDB1 (0.69) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL19661892 | 0.96 | DDB1 (0.69) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL22473672 | 0.95 | DDB1 (0.68) | DDB1CRBNHDAC1HDAC2HDAC3 | |
| SCHEMBL12250757 | 0.95 | DDB1 (0.71) | DDB1CRBNHDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12233054-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240165095-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220362229-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | DDB1 1404/4885CRBN 1/4885HDAC1 2597/4885 |
| US-20220362229-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CD74 | DDB1 1404/4885CRBN 1/4885HDAC1 2597/4885 |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CDR2 | DDB1 2104/4885CRBN 1/4885HDAC1 2621/4885 |
| US-12233054-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | DDB1 1404/4885CRBN 1/4885HDAC1 2597/4885 |
| US-20240165095-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CD74 | DDB1 1404/4885CRBN 1/4885HDAC1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.